Open AccessThe Role of RANK‐Ligand Inhibition in Cancer: The Story of Denosumab
Author(s) -
Castellano Daniel,
Sepulveda Juan Manuel,
GarcíaEscobar Ignacio,
RodriguezAntolín Alfredo,
Sundlöv Anna,
CortesFunes Hernán
Publication year - 2011
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2010-0154
Subject(s) - denosumab , medicine , bone metastasis , osteoclast , rankl , prostate cancer , spinal cord compression , bone resorption , oncology , cancer , activator (genetics) , cancer research , osteoporosis , receptor , spinal cord , psychiatry
The diagnosis of bone metastases is an event with certain consequences for the patient. They often mean pain and can also mean pathological fractures, hypercalcemia, and spinal cord compression, all synonymous with a diminished quality of life and often also hospitalization. Since the advent of the intravenous bisphosphonates, things began to look a bit brighter for patients with bone metastases—bone destruction was kept at bay a little longer. The next generation of bone metastasis treatments is well on its way in clinical development, and among them, the most advanced drug is denosumab. Denosumab is a fully human monoclonal antibody that inhibits osteoclast maturation, activation, and function by binding to receptor activator of nuclear factor kappa B ligand, with the final result being a reduced rate of bone resorption. In this review, we give an overview of relevant preclinical and clinical data regarding the use of denosumab in patients with solid tumors in general and prostate cancer in particular.